Literature DB >> 12775673

AmpC beta-lactamases: what do we need to know for the future?

Nancy D Hanson1.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12775673     DOI: 10.1093/jac/dkg284

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  33 in total

1.  Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases.

Authors:  Jennifer A Black; Kenneth S Thomson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

2.  Concurrent occurrence of blaampC families and blaCTX-M genogroups and association with mobile genetic elements ISEcp1, IS26, ISCR1, and sul1-type class 1 integrons in Escherichia coli and Klebsiella pneumoniae isolates originating from India.

Authors:  Mohammed Shahid; Farrukh Sobia; Anuradha Singh; Haris M Khan
Journal:  J Clin Microbiol       Date:  2012-02-15       Impact factor: 5.948

3.  Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.

Authors:  Wonkeun Song; Ellen S Moland; Nancy D Hanson; James S Lewis; James H Jorgensen; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals.

Authors:  Michael R Mulvey; Elizabeth Bryce; David A Boyd; Marianna Ofner-Agostini; Allison M Land; Andrew E Simor; Shirley Paton
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.

Authors:  Emma Padilla; Diana Alonso; Antonio Doménech-Sánchez; Cristina Gomez; José Luis Pérez; Sebastián Albertí; Nuria Borrell
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy.

Authors:  Marco M D'Andrea; Elisabetta Nucleo; Francesco Luzzaro; Tommaso Giani; Roberta Migliavacca; Francesca Vailati; Vesselina Kroumova; Laura Pagani; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 7.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

8.  AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.

Authors:  Hedi Mammeri; Hasan Nazic; Thierry Naas; Laurent Poirel; Sophie Léotard; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 9.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

10.  Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Kevin B Laupland
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.